种族、民族与肥胖对CAR T细胞治疗结局的影响
该研究回顾性分析了2012至2021年在美国国家癌症研究所5项1期临床试验中接受CAR T细胞治疗的血液恶性肿瘤患者,重点为139例B-ALL输注。研究发现种族、民族或BMI与完全缓解率、神经毒性或总生存无显著关联,但西班牙裔患者发生重度细胞因子释放综合征的几率高于白人非西班牙裔患者(比值比4.5,P=0.001)。
要点
- 在139例B-ALL CAR T细胞输注中,28.8%为西班牙裔,3.6%为黑人,29.5%为超重/肥胖。
- 种族、民族或BMI与完全缓解率、神经毒性或总生存无显著关联。
- 西班牙裔患者较白人非西班牙裔患者更易发生重度细胞因子释放综合征(比值比4.5,P=0.001)。
核心结论
- 研究提示CAR T细胞治疗可能对包括化疗耐药和复发高风险人群在内的多种人口学特征人群提供实质性获益,但毒性特征可能不同。
- 作者认为应优先努力改善代表性不足人群接受CAR治疗的可及性,并阐明不同人口学群体间毒性差异的机制。
研究设计与样本
- 回顾性评估2012至2021年美国国家癌症研究所5项1期临床试验中接受CAR T细胞治疗的成人和儿童血液恶性肿瘤患者的人口学特征和肥胖对结局的影响,主要关注B-ALL患者。
主要发现
- 在139例B-ALL CAR T细胞输注中,28.8%的患者为西班牙裔,3.6%为黑人,29.5%为超重/肥胖。
- 种族、民族或体重指数(BMI)与完全缓解率、神经毒性或总生存之间未发现显著关联。
- 西班牙裔患者较白人非西班牙裔患者更易发生重度细胞因子释放综合征,即使在调整白血病疾病负荷和年龄后亦然(比值比4.5,P=0.001)。
- 对多发性骨髓瘤(n=24)和非霍奇金淋巴瘤(n=23)患者的描述性分析显示与B-ALL队列相似的模式。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer outcomes with chemotherapy are inferior in patients of minority racial/ethnic groups and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for relapsed/refractory hematologic malignancies, but whether its benefits extend commensurately to racial/ethnic minorities and patients with obesity is poorly understood. With a primary focus on patients with B-cell acute lymphoblastic leukemia (B-ALL), we retrospectively evaluated the impact of demographics and obesity on CAR T-cell therapy outcomes in adult and pediatric patients with hematologic malignancies treated with CAR T-cell therapy across 5 phase 1 clinical trials at the National Cancer Institute from 2012 to 2021. Among 139 B-ALL CAR T-cell infusions, 28.8% of patients were Hispanic, 3.6% were Black, and 29.5% were overweight/obese. No significant associations were found between race, ethnicity, or body mass index (BMI) and complete remission rates, neurotoxicity, or overall survival. Hispanic patients were more likely to experience severe cytokine release syndrome compared with White non-Hispanic patients even after adjusting for leukemia disease burden and age (odds ratio, 4.5; P = .001). A descriptive analysis of patients with multiple myeloma (n = 24) and non-Hodgkin lymphoma (n = 23) displayed a similar pattern to the B-ALL cohort. Our findings suggest CAR T-cell therapy may provide substantial benefit across a range of demographics characteristics, including for those populations who are at higher risk for chemotherapy resistance and relapse. However, toxicity profiles may vary. Therefore, efforts to improve access to CAR therapy for underrepresented populations and elucidate mechanisms of differential toxicity among demographic groups should be prioritized.
引用
- Faruqi AJ, Ligon JA, Borgman P, et al. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Adv. 2022. PMID: 35939781. doi:10.1182/bloodadvances.2022007676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。